Preferred Label : Ritlecitinib;

NCIt related terms : JAK3 Inhibitor PF-06651600;

NCIt definition : An orally available small-molecule inhibitor of tyrosine-protein kinase JAK3 (Janus kinase 3; JAK3) with potential immunomodulatory and anti-inflammatory activities. Upon administration, ritlecitinib selectively and irreversibly binds to JAK3 and prevents the activation of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This may decrease the production of certain pro-inflammatory cytokines and prevent both an inflammatory response and the inflammation-induced damage caused by certain immunological diseases. By selectively targeting JAK3, PF-06651600 may spare interleukin (IL)-6 signaling, as well as other JAK1-dependent immunoregulatory cytokines such as IL-10, IL-27, and IL-35, which may offer a safety benefit compared to non-selective JAK inhibitors. JAK kinases are intracellular enzymes involved in signaling pathways affecting hematopoiesis, immunity and inflammation.;

UNII : 2OYE00PC25;

InChIKey : CBRJPFGIXUFMTM-WDEREUQCSA-N;

CAS number : 1792180-81-4; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1792180-81-4 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Molecule name : PF-06651600; PF 06651600;

NCI Metathesaurus CUI : CL970401;

Details


Main resources

You can consult :


https://www.has-sante.fr/jcms/p_3505844/fr/litfulo-ritlecitinib-pelade
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
adult
adolescent
administration, oral
ritlecitinib
Janus Kinase Inhibitors
immunosuppressive agents
evaluation of the transparency committee
Ritlecitinib
alopecia areata

---
https://ansm.sante.fr/tableau-marr/ritlecitinib
2024
false
false
false
France
French
risk management
Ritlecitinib
Drug-Related side effects and adverse reactions
ritlecitinib
guidelines for drug use
patient education handout
administration, oral
Janus Kinase Inhibitors
Immunomodulating Agents

---
https://www.ema.europa.eu/en/medicines/human/EPAR/litfulo
2023
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Ritlecitinib
Ritlecitinib
drug approval
europe
Janus Kinase Inhibitors
Janus Kinase Inhibitors
ritlecitinib
adult
adolescent
alopecia areata
administration, oral
continuity of patient care
immunosuppressive agents
immunosuppressive agents
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
Female of Childbearing Potential
drug evaluation, preclinical

---
Nous contacter.
15/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.